Spero Therapeutics
NASDAQ: SPROCambridge, US · Founded 2013 · Delaware corporation · 45 employees on LinkedIn · 7 known investors
Find your way into Spero Therapeutics
155 people in our graph share verified history with the Spero Therapeutics team — schools, employers, funds. One of them is your warm intro.
Loubaba El Ayoubiunlockedknows Ankit Mahadevia · together at Inductive Bio (overlapped)
knows the team · via Tessera
×6knows the team · via George Mason University
×4knows the team · via The Johns Hopkins University School of Medicine
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease. It focuses on immune signaling pathways involved in inflammation and fibrosis, with potential applications across additional immune-mediated conditions.
Founders & leadership
Spero Therapeutics was founded in 2013 by Ankit Mahadevia.
AM
Ankit MahadeviainFounderAnkit Mahadevia is a physician and entrepreneur with an MD from Johns Hopkins University School of Medicine and an MBA in healthcare management from the Wharton School. He has held leadership roles at multiple biotechnology companies and serves as a strategic advisor to life sciences firms on growth, financing, and organizational development.
SG
Stephen GarbaczinExecutiveStephen Garbacz is an Executive Officer at Spero Therapeutics with extensive biotech finance experience, including roles in treasury, SEC compliance, and strategic planning. A former CPA, he has led multiple IPO preparations, early-stage financings, and finance organizations across clinical-stage companies, while also pursuing advanced training in AI and data science at Stanford and MIT.
ER
Esther RajaveluinDirector, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer
Board
JF
RH
CB
Casper BreumBoard director
VG
PV
Patrick VinkBoard director
MD
Investors · 7
HEALTHCARE ROYALTY PARTNERSNew York
MRL Ventures FundCambridge · $25M
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
RA CapitalBostonvia Reza Halse · board
Alphabetreported · 2 sourcesMountain View
Atlas Venturereported · 2 sourcesCambridge · $500K – $1Mvia Jean-François Formela · board
Fidelity InvestmentsreportedBoston
Reported raises · per SEC filings
Form D private placements$92.2M disclosed across 3 of 4 rounds · 2017–2026
▶$9MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
▶$9MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Milind DeshpandeDirector
- Kamal HamedExecutive Officer
- Scott JacksonDirector
- Tamara JosephExecutive Officer
- Kathleen TregoningDirector
- Patrick VinkDirector
- Satyavrat ShuklaExecutive Officer
- Timothy KeutzerExecutive Officer
- John C. Pottage, Jr.Director
- Ankit MahadeviaExecutive Officer, Director
- Cynthia SmithDirector
- Frank E. ThomasDirector
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40MraisedJul 2021 · 1 investors · BiotechnologyRule 506(b)
▶$40MraisedJul 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Milind DeshpandeDirector
- David MelnickExecutive Officer
- Patrick VinkDirector
- Cynthia SmithDirector
- Satyavrat ShuklaExecutive Officer
- Tamara JosephExecutive Officer
- Scott JacksonDirector
- Timothy KeutzerExecutive Officer
- Frank E. ThomasDirector
- Cristina LarkinExecutive Officer
- John C. Pottage, Jr.Director
- Ankit MahadeviaExecutive Officer, Director
- Jean-Francois FormelaDirector
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$43.2MraisedMar 2017 · 11 investors · BiotechnologyRule 506(b)
▶$43.2MraisedMar 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick VinkDirector
- Milind DeshpandeDirector
- Jean-Francois FormelaDirector
- Reza HalseDirector
- Casper BreumDirector
- Ankit MahadeviaExecutive Officer, Director
- Stephen GarbaczExecutive Officer
- Vikas GoyalDirector
- Offering amount
- $43.2M
- Amount sold
- $43.2M
- First sale
- Mar 2017
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$179.7Mvaluation at IPOJul 2018 · $12.50/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlap
Sarepta Therapeutics33 shared keywordsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
Spyre Therapeutics31 shared keywordsSpyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.
Solu29 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Seeking Alpha25 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Spero Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Spero Therapeutics do?
- Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease. It focuses on immune signaling pathways involved in inflammation and fibrosis, with potential applications across additional immune-mediated conditions.
- Who founded Spero Therapeutics?
- Spero Therapeutics was founded by Ankit Mahadevia in 2013.
- Who are Spero Therapeutics's investors?
- Spero Therapeutics's investors include HEALTHCARE ROYALTY PARTNERS, MRL Ventures Fund, OUP (Osage University Partners), RA Capital, Alphabet, Atlas Venture, Fidelity Investments.
- How much funding has Spero Therapeutics raised?
- Spero Therapeutics has disclosed $92.2M raised across 3 of its 4 known rounds.
- Where is Spero Therapeutics headquartered?
- Spero Therapeutics is headquartered in Cambridge, US.